Tomasz Krzywicki

Dr. Tomasz Krzywicki

Mathematics and Computer Science, University of Warmia and Mazury in Olsztyn, Olsztyn, Warmińsko-Mazurskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in Ophthalmic Research
Verified
Journal Article
Open access
PDF file
Andrzej GrzybowskiAndrzej Grzybowski
Andrzej Grzybowski
DRDivya Parthasarathy Rao
Divya Parthasarathy Rao
PBPiotr Brona
Piotr Brona
KNKalpa Negiloni
Kalpa Negiloni
TKTomasz Krzywicki
Tomasz Krzywicki
FSFlorian M. Savoy
Florian M. Savoy
Introduction: Numerous studies have demonstrated the use of artificial intelligence (AI) for early detection of referable diabetic retinopathy (RDR). A direct comparison of these multiple automated diabetic retinopathy (DR) image assessment softwares (ARIAs) is, however, challenging. We retrospectively compared the performance of two modern ARIAs, IDx-DR and Medios AI. Methods: In this retrospective-comparative study, retinal images with sufficient image quality were run on both ARIAs. They were captured in 811 consecutive patients with diabetes visiting diabetic clinics in Poland. For each patient, four non-mydriatic images, 45° field of view, i.e., two sets of one optic disc and one macula-centered image using Topcon NW400 were captured. Images were manually graded for severity of DR as no DR, any DR (mild non-proliferative diabetic retinopathy [NPDR] or more severe disease), RDR (moderate NPDR or more severe disease and/or clinically significant diabetic macular edema [CSDME]), or sight-threatening DR (severe NPDR or more severe disease and/or CSDME) by certified graders. The ARIA output was compared to manual consensus image grading (reference standard). Results: On 807 patients, based on consensus grading, there was no evidence of DR in 543 patients (67%). Any DR was seen in 264 (33%) patients, of which 174 (22%) were RDR and 41 (5%) were sight-threatening DR. The sensitivity of detecting RDR against reference standard grading was 95% (95% CI: 91, 98%) and the specificity was 80% (95% CI: 77, 83%) for Medios AI. They were 99% (95% CI: 96, 100%) and 68% (95% CI: 64, 72%) for IDx-DR, respectively. Conclusion: Both the ARIAs achieved satisfactory accuracy, with few false negatives. Although false-positive results generate additional costs and workload, missed cases raise the most concern whenever automated screening is debated.

14 July 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
AZAgnieszka Malgorzata Zbrzezny
Agnieszka Malgorzata Zbrzezny
TKTomasz Krzywicki
Tomasz Krzywicki
The use of artificial intelligence (AI) in dermatology is skyrocketing, but a comprehensive overview integrating regulatory, ethical, validation, and clinical issues is lacking. This work aims to review current research, map applicable legal regulations, identify ethical challenges and methods of verifying AI models in dermatology, assess publication trends, compare the most popular neural network architectures and datasets, and identify good practices in creating AI-based applications for dermatological use. A systematic literature review is conducted in accordance with the PRISMA guidelines, utilising Google Scholar, PubMed, Scopus, and Web of Science and employing bibliometric analysis. Since 2016, there has been exponential growth in deep learning research in dermatology, revealing gaps in EU and US regulations and significant differences in model performance across different datasets. The decision-making process in clinical dermatology is analysed, focusing on how AI is augmenting skin imaging techniques such as dermatoscopy and histology. Further demonstration is provided regarding how AI is a valuable tool that supports dermatologists by automatically analysing skin images, enabling faster diagnosis and the more accurate identification of skin lesions. These advances enhance the precision and efficiency of dermatological care, showcasing the potential of AI to revolutionise the speed of diagnosis in modern dermatology, sparking excitement and curiosity. Then, we discuss the regulatory framework for AI in medicine, as well as the ethical issues that may arise. Additionally, this article addresses the critical challenge of ensuring the safety and trustworthiness of AI in dermatology, presenting classic examples of safety issues that can arise during its implementation. The review provides recommendations for regulatory harmonisation, the standardisation of validation metrics, and further research on data explainability and representativeness, which can accelerate the safe implementation of AI in dermatological practice.

6 November 2024 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
Andrzej GrzybowskiAndrzej Grzybowski
Andrzej Grzybowski
PBPiotr Brona
Piotr Brona
TKTomasz Krzywicki
Tomasz Krzywicki
PRPaisan Ruamviboonsuk
Paisan Ruamviboonsuk
Introduction: Automated diabetic retinopathy (DR) screening using artificial intelligence has the potential to improve access to eye care by enabling large-scale screening. However, little is known about differences in real-world performance between available algorithms. This study compares the diagnostic accuracy of two AI screening platforms, IDx-DR and RetCAD, for detecting referable diabetic retinopathy (RDR). Methods: Retinal images from 758 patients with diabetes were collected during screening from various clinics in Poland. Each patient was graded by three graders with 320 patients graded by Polish and 438 patients graded by Indian graders, with the majority decision serving as the reference standard. The images were evaluated independently by the IDx-DR and RetCAD algorithms. Sensitivity, specificity, positive and negative predictive values, and agreement between algorithms and human graders were calculated and statistically compared. Results: IDx-DR demonstrated higher sensitivity of 99.3% but lower specificity of 68.9% for RDR detection compared to RetCAD which had 89.4% sensitivity and 94.8% specificity. The positive predictive value was higher for RetCAD (96.4% vs 48.1% for IDx-DR) while the negative predictive value was higher for IDx-DR (99.5% vs 83.1% for RetCAD). Both algorithms achieved high sensitivity (> 95%) for sight-threatening diabetic retinopathy detection. Conclusion: In this direct comparison using the same patient cohort, the two algorithms showed differences in their operating parameters for RDR screening. IDx-DR prioritized avoiding false negatives over false positives while RetCAD maintained a more balanced trade-off. These results highlight the variable performance of current artificial intelligence screening solutions and suggest the importance of considering algorithm performance metrics when deploying automated diabetic retinopathy screening programs, based on available healthcare resources.

Verified
Journal Article
Open access
PDF file
TKTomasz Krzywicki
Tomasz Krzywicki
PBPiotr Brona
Piotr Brona
AZAgnieszka Malgorzata Zbrzezny
Agnieszka Malgorzata Zbrzezny
Andrzej GrzybowskiAndrzej Grzybowski
Andrzej Grzybowski
This article provides a comprehensive and up-to-date overview of the repositories that contain color fundus images. We analyzed them regarding availability and legality, presented the datasets’ characteristics, and identified labeled and unlabeled image sets. This study aimed to complete all publicly available color fundus image datasets to create a central catalog of available color fundus image datasets.

Verified
Journal Article
Open access
PDF file
Andrzej GrzybowskiAndrzej Grzybowski
Andrzej Grzybowski
PBPiotr Brona
Piotr Brona
TKTomasz Krzywicki
Tomasz Krzywicki
MGMagdalena Gaca-Wysocka
Magdalena Gaca-Wysocka
ABArleta Berlińska
Arleta Berlińska
AŚAnna Święch
Anna Święch
Poland has never had a widespread diabetic retinopathy (DR) screening program and subsequently has no purpose-trained graders and no established grader training scheme. Herein, we compare the performance and variability of three retinal specialists with no additional DR grading training in assessing images from 335 real-life screening encounters and contrast their performance against IDx-DR, a US Food and Drug Administration (FDA) approved DR screening suite. A total of 1501 fundus images from 670 eyes were assessed by each grader with a final grade on a per-eye level. Unanimous agreement between all graders was achieved for 385 eyes, and 110 patients, out of which 98% had a final grade of no DR. Thirty-six patients had final grades higher than mild DR, out of which only two had no grader disagreements regarding severity. A total of 28 eyes underwent adjudication due to complete grader disagreement. Four patients had discordant grades ranging from no DR to severe DR between the human graders and IDx-DR. Retina specialists achieved kappa scores of 0.52, 0.78, and 0.61. Retina specialists had relatively high grader variability and only a modest concordance with IDx-DR results. Focused training and verification are recommended for any potential DR graders before assessing DR screening images.

10 December 2024 in Acta Ophthalmologica
Verified
Journal Article
Closed access
Andrzej GrzybowskiAndrzej Grzybowski
Andrzej Grzybowski
FPFreya Peeters
Freya Peeters
RBRafael Correia Barão
Rafael Correia Barão
PBPiotr Brona
Piotr Brona
SRStef Rommes
Stef Rommes
JJJulie Jacob
Julie Jacob